Lung hypofractionated squamous carcinoma is a malignant tumor with relatively high degree of malignancy, which is prone to metastasis at early stage, with low cure rate and poor prognosis, and the possibility of surviving for 20 years is relatively low, though it is not precisely stated in the clinic, and it should be analyzed with the control of the patient’s condition as well as his/her personal situation. The survival time of lung low-differentiated squamous carcinoma is uncertain, which depends on the patient’s physical condition and treatment effect, and cannot be generalized. Patients need to go to the hospital for regular checkups and adopt the best treatment plan according to their personal conditions. At present, surgery, radiotherapy, chemotherapy and immunotherapy can be adopted to control the cancer cells and prolong the survival time. The survival rate of lung low-differentiated squamous carcinoma is relatively higher without lymph node metastasis and blood line metastasis, and if it has already metastasized or spread to other parts of the body, the survival rate will be significantly lower. At present, patients should actively cooperate with the treatment so as not to delay the condition.